Success Metrics

Clinical Success Rate
82.6%

Based on 38 completed trials

Completion Rate
83%(38/46)
Active Trials
1(2%)
Results Posted
58%(22 trials)
Terminated
8(14%)

Phase Distribution

Ph phase_1
4
7%
Ph not_applicable
5
8%
Ph early_phase_1
2
3%
Ph phase_2
7
12%
Ph phase_3
15
25%
Ph phase_4
25
42%

Phase Distribution

6

Early Stage

7

Mid Stage

40

Late Stage

Phase Distribution58 total trials
Early Phase 1First-in-human
2(3.4%)
Phase 1Safety & dosage
4(6.9%)
Phase 2Efficacy & side effects
7(12.1%)
Phase 3Large-scale testing
15(25.9%)
Phase 4Post-market surveillance
25(43.1%)
N/ANon-phased studies
5(8.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.9%

38 of 47 finished

Non-Completion Rate

19.1%

9 ended early

Currently Active

1

trials recruiting

Total Trials

59

all time

Status Distribution
Active(2)
Completed(38)
Terminated(9)
Other(10)

Detailed Status

Completed38
unknown9
Terminated8
Enrolling by invitation1
Recruiting1
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
59
Active
1
Success Rate
82.6%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (3.4%)
Phase 14 (6.9%)
Phase 27 (12.1%)
Phase 315 (25.9%)
Phase 425 (43.1%)
N/A5 (8.6%)

Trials by Status

enrolling_by_invitation12%
recruiting12%
suspended12%
completed3864%
unknown915%
withdrawn12%
terminated814%

Recent Activity

Clinical Trials (59)

Showing 20 of 59 trialsScroll for more
NCT07268170Phase 2

Heart Rate Control Before Cardiac Computed Tomography in Adults for the Evaluation of Coronary Artery Disease

Enrolling By Invitation
NCT02479204Phase 1

Clinical Study to Investigate Safety and Effects on Heart Rate, Blood Pressure, and Pharmacokinetic Interactions of ACT-334441

Terminated
NCT04755764

Effect of Labetalol, Atenolol, and Nifedipine on Maternal Hemodynamics Measured by ICG in Early Pregnancy

Recruiting
NCT00429364Phase 3

Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome

Completed
NCT02560805Phase 2

Role of Sympathetic Overactivity and Angiotensin II in PTSD and CV

Suspended
NCT03578354Phase 2

4-Aminopyridine, Atenolol, or Placebo in Patients With Vestibular Migraine

Withdrawn
NCT04931108Phase 4

The Effect of Nitrendipine/Atenolol Combination on Blood Pressure Variability.

Unknown
NCT03082014Phase 3

Effects of Amlodipine and Other Blood Pressure Lowering Agents on Microvascular Function

Terminated
NCT02342275Phase 3

Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma

Completed
NCT00535925Phase 4

Nephropathy In Type 2 Diabetes and Cardio-renal Events

Completed
NCT01522950Phase 2

A Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function

Completed
NCT04224675Not Applicable

Captopril Versus Atenolol to Prevent Expansion Rate of Thoracic Aortic Aneurysms

Unknown
NCT00125853Not Applicable

The Effect of Nebivolol on Insulin Sensitivity

Completed
NCT00925119Phase 4

Examining Genetic Influence on Response to Beta-Blocker Medications in People With Type 2 Diabetes

Terminated
NCT01202721Phase 3

Beta Blockers and Angiotensin Receptor Blockers in Bicuspid Aortic Valve Disease Aortopathy (BAV Study)

Terminated
NCT01719367Not Applicable

Genetically Determined Response to Atenolol in Patients With Persistent Atrial Fibrillation

Completed
NCT02467400Early Phase 1

Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism

Completed
NCT01132768Phase 4

The Confirmatory Olmesartan Plaque Regression Study

Terminated
NCT00246519Phase 4

Pharmacogenomic Evaluation of Antihypertensive Responses

Completed
NCT03147092Early Phase 1

Matão Controlling Hypertension (MatCH Study): Rationale and Design

Unknown

Drug Details

Intervention Type
DRUG
Total Trials
59